ImmuPharma Puts On Very Brave Face After Lupus Drug Flop
Executive Summary
Shares in the UK biotech have fallen through the floor following a failed Phase III trial of Lupuzor but ImmuPharma remains surprisingly upbeat about the lupus drug's prospects.
You may also be interested in...
ImmuPharma secures £50m to develop ex-Cephalon asset
ImmuPharma has secured a £50 million, five-year equity financing facility to fund its late stage lupus treatment. This will allow the company to complete Phase III development of Lupuzor.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.